Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21020731 | 1.00 | MAPK1 (0.59) | MAPK1HIF1ANPC1MAPTCA12 | |
| SCHEMBL15963820 | 1.00 | MAPK1 (0.59) | MAPK1HIF1ANPC1MAPTCA12 | |
| SCHEMBL15963822 | 1.00 | MAPK1 (0.59) | MAPK1HIF1ANPC1MAPTCA12 | |
| SCHEMBL17331173 | 1.00 | MAPK1 (0.59) | MAPK1HIF1ANPC1MAPTCA12 | |
| Hydrochloric Acid SCHEMBL30185779 | 0.98 | MAPK1 (0.57) | MAPK1HIF1ANPC1MAPTCA12 | |
| SCHEMBL19629286 | 0.98 | MAPK1 (0.60) | MAPK1HIF1ANPC1MAPTCA12 | |
| SCHEMBL22691913 | 0.93 | MAPK1 (0.59) | MAPK1HIF1ANPC1MAPTCA12 | |
| SCHEMBL22691906 | 0.91 | MAPK1 (0.64) | MAPK1HIF1ANPC1MAPTCA12 | |
| SCHEMBL17331198 | 0.90 | MAPK1 (0.73) | MAPK1HIF1ANPC1MAPTALDH1A1 | |
| SCHEMBL17331168 | 0.90 | MAPK1 (0.73) | MAPK1HIF1ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913726-B2 | Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-09 | — | — | US | disclosed |
| US-10800749-B2 | Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190337911-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-11-07 | — | — | US | disclosed |
| US-20190119237-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
| EP-2956451-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | The Regents of the University of California (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150361060-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-17 | — | — | US | disclosed |
| WO-2014127315-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800749-B2 | Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them | ACHE, BCHE, IDE | MAPK1 3403/4885HIF1A 4152/4885NPC1 3210/4885 |
| US-20190337911-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | ACHE, BCHE, IDE | MAPK1 3403/4885HIF1A 4152/4885NPC1 3210/4885 |
| US-20150361060-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | ACHE, BCHE, IDE | MAPK1 3403/4885HIF1A 4152/4885NPC1 3210/4885 |
| US-20190119237-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM | ACHE, BCHE, IDE | MAPK1 3403/4885HIF1A 4152/4885NPC1 3210/4885 |
| US-10913726-B2 | Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them | ACHE, BCHE, IDE | MAPK1 3403/4885HIF1A 4152/4885NPC1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.